Clinical trial
A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines
NCT00076063 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00076063 |
|---|---|
| Title | A Study of LIPO-5 and ALVAC-HIV (vCP1452) as Possible HIV Vaccines |
| Official title | A Phase I/II Clinical Trial to Evaluate the Safety and Immunogenicity of LIPO-5 Alone, ALVAC-HIV (vCP1452) Alone, and ALVAC Prime/LIPO-5 Boost in Healthy, HIV-1 Uninfected Adult Participants |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Collaborators | ANRS, Emerging Infectious Diseases |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections |
| Intervention type | Biological |
| Interventions | ALVAC-HIV (vCP1452), LIPO-5 |
| Enrollment | 174 |
| Start date | Mar 1, 2004 |
| Completion | Mar 1, 2007 |
| First posted | Jan 14, 2004 |
| Last update posted | Oct 14, 2021 |
| Countries | United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: